Saw palmetto extract clinical trials
Also written Saw Palmetto.
How each study uses saw palmetto extract is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 1999 (1)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Pierre Fabre Medicament (2) · RDC Clinical Pty Ltd (1) · Michigan State University (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
Studies
Open first, then newest update. How each study uses saw palmetto extract is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Comparison of 2 Extracts of Saw Palmetto Versus Placebo on Lower Urinary Tract Symptoms (LUTS) and Urinary FrequencyCompletedPhase 4RDC Clinical Pty LtdNCT06266000Written as Saw palmetto extract 320mg per dayHow we know
- Saw Palmetto: Symptom Management for Men During Radiation TherapyCompletedPhase 1/2Michigan State UniversityNCT01585246Written as Saw PalmettoHow we know
- PERmixon® in LUTS Evaluation Study (PERLES)CompletedPhase 4Pierre Fabre MedicamentNCT02121613Written as Permixon® 160 mgHow we know
- Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)CompletedPhase 4Pierre Fabre MedicamentNCT01604811Written as Permixon® 160 mgHow we know
- Saw Palmetto Extract in Benign Prostatic HyperplasiaCompletedPhase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00037154Written as Saw PalmettoHow we know
Codes
What other systems call saw palmetto extract · ClinicalTrials.gg INT003139
- MeSH (NLM) C040972saw palmetto extractConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) J7WWH9M8QSSAW PALMETTOOne source NLM
- RxNorm 477189One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C040972 | saw palmetto extract | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | J7WWH9M8QS | SAW PALMETTO | One source NLM |
| RxNorm | 477189 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.